February 22, 2017


Multiple Sclerosis Patients See Drug Value Differently Than Payers and Doctors

By Ed Silverman

When it comes to medicines, value is often in the eye of the beholder. A new analysis finds that what multiple sclerosis patients value in their medicines is generally overlooked by payers and doctors. As a result, drug companies subsequently disregard what matters most to patients, according to Real Endpoints, a research firm that conducted the analysis.

read full article >